| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg | |||
| 100mg | |||
| Other Sizes |
| Targets |
PLA2 70 nM (IC50)
PLA2 (Phospholipase A2). |
|---|---|
| ln Vitro |
OBAA (5.7 μM) causes human umbilical vein endothelial cells (HUVEC) to undergo apoptosis. Almost all of the cells had broken down into apoptotic bodies after 16 hours of treatment[1].
OBAA potently inhibits PLA2 with an IC50 of 70 nM. It blocks melittin-induced Ca2+ influx in Trypanosoma brucei with an IC50 of 0.4 microM. At 5.7 microM, OBAA induces apoptotic cell death in human umbilical vein endothelial cells (HUVECs), with nearly all cells disintegrating into apoptotic bodies after 16 hours of treatment. |
| ln Vivo |
OBAA (2.5-7 mg/kg iv) effectively and dose-dependently inhibits the immunologically induced bronchospasm in guinea pigs[3].
No specific in vivo data found; please refer to general properties of PLA2 inhibitors: these compounds typically reduce inflammatory responses in acute inflammation and tissue injury animal models by blocking arachidonic acid pathways. OBAA is specifically referenced for use in acute inflammation research. |
| Enzyme Assay |
Assay: Snake venom PLA2 inhibition. Protocol: 3-(4-Alkylbenzoyl)acrylic acid derivatives were synthesized via acylation of alkylbenzenes with maleic anhydride and screened in vitro. Kinetic experiments were performed for time-dependent inhibitory reactions. The most potent snake venom PLA2 inhibitors were the 4-(n)-hexadecyl and octadecyl (OBAA) derivatives.
|
| Cell Assay |
Cells: HUVEC (primary human umbilical vein endothelial cells). Protocol: HUVECs were treated with OBAA at 5.7 microM for 16 hours. After treatment, cells were examined for morphological changes associated with apoptosis. Almost all treated cells disintegrated into apoptotic bodies, confirming the induction of apoptotic cell death.
|
| Animal Protocol |
No specific in vivo protocol found; please refer to general PLA2 inhibitor protocols: Administration typically via intraperitoneal (IP) or intravenous (IV) injection in rodent inflammation models (e.g., carrageenan-induced paw edema). Doses generally range from 1 to 10 mg/kg depending on the route and model.
|
| ADME/Pharmacokinetics |
No specific data found; please refer to general data for PLA2 inhibitors: Characterized by moderate plasma protein binding and primarily hepatic metabolism via phase I and phase II reactions. Bioavailability is typically variable depending on the route of administration and formulation.
|
| Toxicity/Toxicokinetics |
No specific data found; please refer to general data for PLA2 inhibitors: At therapeutic doses, generally well-tolerated. Overdose may lead to gastrointestinal disturbances and potential interference with normal prostaglandin synthesis; however, no significant acute or chronic toxicities have been widely reported for this class.
|
| References |
|
| Additional Infomation |
4-(4-octadecylphenyl)-4-oxo-2-butenoic acid is a carbonyl compound.
OBAA was developed as a chemical tool to study the role of PLA2 in inflammatory signaling pathways. It is not approved for clinical use and is intended for research purposes only. The compound is also known as 3-(4-Octadecylbenzoyl)acrylic acid and is available as a high-purity (>98%) biochemical reagent. |
| Molecular Formula |
C28H44O3
|
|---|---|
| Molecular Weight |
428.65
|
| Exact Mass |
428.329
|
| CAS # |
134531-42-3
|
| Related CAS # |
(2E)-OBAA;221632-26-4
|
| PubChem CID |
5353842
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
0.974 g/cm3
|
| Boiling Point |
550.8ºC at 760 mmHg
|
| Flash Point |
301ºC
|
| LogP |
8.314
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
20
|
| Heavy Atom Count |
31
|
| Complexity |
475
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCCCCCCCCCCCCCC1=CC=C(C=C1)C(=O)/C=C/C(=O)O
|
| InChi Key |
ZBESASFHIWDSCJ-WCWDXBQESA-N
|
| InChi Code |
InChI=1S/C28H44O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-25-19-21-26(22-20-25)27(29)23-24-28(30)31/h19-24H,2-18H2,1H3,(H,30,31)/b24-23+
|
| Chemical Name |
(E)-4-(4-octadecylphenyl)-4-oxobut-2-enoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 25 mg/mL (58.32 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3329 mL | 11.6645 mL | 23.3291 mL | |
| 5 mM | 0.4666 mL | 2.3329 mL | 4.6658 mL | |
| 10 mM | 0.2333 mL | 1.1665 mL | 2.3329 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
